Privilège Ventures

Privilege Ventures SA is a Swiss, FINMA-authorized early-stage venture capital firm founded in 2016 and headquartered in Lugano, Switzerland, with additional offices in Zurich and Boston. It is the venture capital arm of Privilege Management and is widely recognized as Switzerland's first female-led venture capital firm. The firm's investment thesis is grounded in a data-driven rationale: gender-mixed teams and women-led companies produce better financial outcomes, and Privilege frames this as an economic-return argument rather than a fairness one. The team of approximately ten people, including four Partners and two Venture Partners, spans Switzerland and Italy and brings deep expertise in entrepreneurship, management, finance, and governance. Privilege Ventures invests at seed and early-stage across three thematic pillars: healthtech, agrifood technology, and cleantech, with additional exposure to industrial tech, med-tech, wearables, and broader ICT. Its geographic footprint covers Switzerland and the rest of Europe, with selective Boston-based investments. The firm has approximately 40 portfolio companies. Notable names include Xsensio (wearable skin-chemistry monitoring, most recent disclosed investment March 2026), Adiposs (CHF 4 million Series A, June 2025), AgroSustain, Enantios, SONIX (May 2025), and SMEETZ (March 2025). Beyond capital, Privilege Ventures provides strategic support and mentorship throughout the investment lifecycle, with particular depth in helping portfolio companies navigate Swiss and European regulatory environments and institutional sales. Its status as Switzerland's first female-led VC has generated a differentiated LP base and a co-investor network that values diversity-aligned deal flow, creating a reinforcing pipeline advantage in sourcing and winning competitive seed rounds from underrepresented founding teams across the European life sciences and deep-tech ecosystem.